Cancer remains one of humanity’s most complex challenges. For generations, physicians have made treatment decisions based largely on what they could see under a microscope, where a tumor originated and how similar patients responded in the past.
Today, that paradigm is changing. We are entering an era where cancer can be understood at the molecular level, revealing the unique biology that drives each patient’s disease. At Caris Life Sciences, we believe every cancer patient deserves that deeper understanding because every cancer is biologically unique.
That belief guides everything we do. From our Phoenix laboratory, which has more clinical sequencing capacity than any other facility in the world, Caris profiles nearly 1,000 cancer patients every day using comprehensive whole exome and whole transcriptome sequencing technologies. To date, our molecular profiling has helped guide treatment decisions for more than one million cancer patients worldwide. Rather than examining only a small subset of genes, we analyze the full molecular blueprint of a patient’s cancer to help physicians identify therapies that provide the greatest potential benefit.
The pace of innovation in oncology is extraordinary. New targeted therapies, immunotherapies and biomarker-driven treatment options are being introduced at an unprecedented rate. While this progress is creating new hope for patients, it is also creating tremendous complexity for physicians and patients navigating difficult treatment decisions. Our role is to help transform that complexity into clarity.
In addition to tissue-based testing, Caris now analyzes cancer-associated markers directly from a patient’s blood plasma, reducing the need for invasive biopsies while providing valuable clinical insights. We recently expanded our capabilities with Caris ChromoSeq™, a whole genome sequencing platform designed specifically for hematologic cancers, and Caris Clarity™, an artificial intelligence-powered technology that analyzes tumor images from early-stage breast cancer patients to help predict the probability of recurrence. We also launched Caris Detect™, a multi-cancer early detection blood test designed to identify cancers at earlier stages, when treatment can be most effective.
The future of precision medicine is being shaped not only by advances in molecular science, but also by artificial intelligence. Modern genomic profiling generates enormous amounts of data, and AI is helping uncover patterns that were previously invisible. Together, these technologies are creating new opportunities to personalize treatment, improve outcomes and, ultimately, detect disease earlier than ever before.
Synergy in the Ecosystem
That future is being built here in the Phoenix area. Arizona has emerged as one of the nation’s most dynamic bioscience ecosystems. What makes the region unique is the collaborative culture among healthcare providers, universities, research institutions and technology innovators.
At Caris, we are fortunate to work alongside outstanding partners that include Arizona State University, Mayo Clinic in Arizona, Barrow Neurological Institute, HonorHealth, Dignity Health and Banner Health. Our growing collaboration with ASU spans precision medicine research, artificial intelligence and bioinformatics, areas that will increasingly define the future of healthcare innovation.
These partnerships matter because modern healthcare challenges cannot be solved by any one organization alone. The next generation of breakthroughs will require expertise across molecular biology, clinical medicine, computational science, software engineering and advanced analytics. Greater Phoenix has become a place where those disciplines increasingly intersect.
The Now & Future Biosciences Hub
The impact extends far beyond scientific discovery. The bioscience sector is creating high-quality jobs, attracting investment and highly skilled talent, and helping diversify Arizona’s economy. Continued growth will depend on sustained investment in education, workforce development and research partnerships that prepare the next generation of scientists, clinicians and technology leaders.
I am optimistic because the pieces are coming together. The scientific tools are more powerful than ever before. Artificial intelligence is accelerating discovery, and the collaboration across Arizona’s healthcare and research communities continues to deepen.
Most importantly, every advance brings us closer to a future where more patients receive the right treatment at the right time, cancers are detected earlier and more families have the opportunity to celebrate milestones that once seemed uncertain. That is the promise of precision medicine, and Greater Phoenix is helping lead the way.
David Spetzler, M.S., MBA, Ph.D.
President
Caris Life Sciences
Read all the bioindustry stories.
